Navigation Links
BioMS Medical to present at BIO CEO and Investor Conference
Date:2/5/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York.

    WHEN:     Monday February 9th at 2:45pm (Eastern Time)

    WHERE:    Waldorf-Astoria, New York City


    About BIO CEO & Investor Conference
    -----------------------------------
    This conference aims to bring together institutional investors, industry
analysts, and senior biotechnology executives in a neutral and collaborative
forum to examine investment opportunities and issues affecting the industry.
For more information visithttp://ceo.bio.org/opencms/ceo/2009/index.jsp.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that ma
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
2. BioMS Medical recognized at Scrip Awards 2008
3. BioMS Medical Announces Third Quarter 2008 Results
4. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
8. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
9. BioMS Medical to present at UBS Global Life Sciences Conference
10. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... CHICAGO , Aug. 1. 2014 As ... U.S., the 2014 AACC Annual Meeting & Clinical Lab ... testing and patient care are introduced to the healthcare ... by the Expo,s 650 exhibitors will include the latest ... Advances in smartphones and biosensors have enabled ...
(Date:8/1/2014)... 2014 The  PROPEL Center  of the  iBIO ... rate of early-stage life sciences companies in ... 15 grants to help Illinois ...   in Chicago .   AdvaMed ... North America , bringing more than 1,000 ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:8/1/2014)... Glencoe Software, Inc. is pleased ... ( http://glencoesoftware.com/data-inpress.html ), a suite of data ... into on-line publications.  The suite comprises Glencoe ... Photo - http://photos.prnewswire.com/prnh/20140731/132410   ... The DataViewer is a browser-based ...
Breaking Biology Technology:Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
... (Nasdaq,CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today,reported results for ... and Recent Company Highlights, -- Follow-on Biologics Program ... Factor or G-CSF) ... products to enter clinical trials in 2008; ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Officer, will participate in a roundtable discussion,"An Industry ... in,Global Health Product Development," and present an overview ... on Tuesday,March 11, at the Biotechnology Industry Organization ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Vical to Present at BIO and BVGH Global Health Partnering Event 2Vical to Present at BIO and BVGH Global Health Partnering Event 3
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... An important step has been made to help better identify ... both an abnormal narrowing and enlarging of medium sized arteries ... kidneys and other organs causing damage. In a new report ... Journal , scientists provide evidence that that FMD may ... addition, they show a connection to abnormalities of bones and ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... A method to detect contaminants in municipal water supplies ... Laboratory researchers whose findings are published on line in ... demonstrates that the technology that uses algae as sentinels ... Miguel Rodriguez Jr. and Elias Greenbaum of the Department ...
... Calif., August 27, 2009 -- Researchers at Burnham ... Southwestern Medical Center and University of Maryland have ... many bacteria can be targeted to kill dangerous ... can inhibit this enzyme and suppress the growth ...
... A new candidate gene for Specific Language Impairment has ... Rice at the University of Kansas, in collaboration with ... Gayn of Neocodex, Seville, Spain. The finding, reported in ... Disorders , was discovered by examining genes previously identified ...
Cached Biology News:ORNL scientists hone technique to safeguard water supplies 2The path to new antibiotics 2Researchers report gene associated with language, speech and reading disorders 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Immunogen: Goats were immunized ... Antibody was isolated by affinity chromatography using ... anti- human T7 affinity purified antibodies were ... method. Specificity: Antibody ...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Biology Products: